The CDC already recommends the RSV shot for all adults 75 and older and for people 60 and older who have health conditions that increase their risk of severe RSV.

In a new consensus statement, the European Society of Cardiology has declared vaccinations for common infections to be a ...

An RSV vaccine during pregnancy and another antibody shot called clesrovimab that can be given to newborns have previously been approved by the Food and Drug Administration and recommended by the ...

Moderna's RSV vaccine gets expanded approval for 18-59 year olds at high risk of severe illness, marking a significant step in vaccine protection.

The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on Thursday to include adults under the age of 60 at increased risk of the disease.

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include adults aged 18 to 59 who are at high risk of severe illness if they ...

June 26 (UPI) -- Merck's Enflonsia vaccine for respiratory syncytial virus won approval from the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices.

Enflonsia joins a handful of other tools recently made available to protect babies from, although the FDA put RSV vaccine trials involving infants and young children ages 2 to 5 on hold last year ...

The Food and Drug Administration (FDA) has expanded the approval of mResvia (respiratory syncytial virus [RSV] vaccine) to include active immunization in individuals 18 through 59 years of age who ...

Expanded Approval: Moderna’s mRESVIA vaccine is now FDA-approved for adults aged 18–59 years with an increased risk for respiratory syncytial virus (RSV)-related lower respiratory tract disease.

Moderna's RSV vaccine gets expanded approval for 18-59 year olds at high risk of severe illness, marking a significant step in vaccine protection.